Lung Cancer Therapy Market Size Report | Global Forecasts till 2030
肺癌治疗市场预计将从 2022 年的 310.1832 亿美元增长到 2030 年的 804.9384 亿美元;预计 2022 年至 2030 年的复合年增长率为 12.7%。
市场洞察和分析师观点:
随着肺癌病例的增加以及英国、德国、美国和印度等国家吸烟和烟草消费习惯的增加,肺癌治疗市场规模正在扩大。在英国,每年约有 48,000 人被诊断出患有肺癌,约有 35,000 人死于肺癌。吸烟是肺癌最常见的原因,而其他原因包括被动吸烟和接触某些气体和化学物质。目前,德国四分之一的男性(约 27.0%)和五分之一的女性(约 21%)经常吸烟。目前肺癌治疗的前景光明,有多种药物获批、丰富的产品线和许多正在进行的临床试验。多种肺癌疗法正处于临床开发的不同阶段;制药巨头正在努力扩大其产品线,这是肺癌治疗市场的一个重大机遇
增长动力和挑战:
肺癌是全球主要死亡原因之一。如果及早诊断,这种癌症可以得到更有效的治疗。因此,患肺癌风险高的人需要接受常规检查,以检测肺部是否形成癌变。在全球范围内,肺癌是男性中最常见的癌症,也是女性中第二常见的癌症。根据世界卫生组织 (WHO) 的数据,肺癌是全球男性和女性癌症相关死亡的主要原因。根据世界癌症研究基金会国际数据,2020 年全球新增肺癌病例约 220 万例。
根据美国癌症协会对美国肺癌的估计,2023 年可能会登记约 238,340 例新的肺癌病例,其中包括 120,790 名女性和 117,550 名男性。此外,根据美国国家生物技术信息中心 ( NCBI ) 的数据,意大利每年记录约 41,000 例新诊断的肺癌病例和约 34,000 例死亡病例。根据澳大利亚癌症协会 2023 年的报告,2022 年诊断出约 14,529 例新的肺癌病例,其中包括 7,707 名男性和 6,822 名女性。近 9% 的新癌症病例是在 2022 年诊断出来的,估计有 8,664 人死亡。土耳其卫生部提供的数据显示,土耳其每年约有 23,000 名男性和约 4,500 名女性被诊断出患有肺癌。因此,全球肺癌发病率的上升促进了肺癌治疗的研究和开发活动,进而推动了市场的增长。
自 1995 年以来,由于生物制剂在肿瘤学中的应用,新型抗癌药物的价格显著上涨。在美国,治疗癌症的每月费用约为 100,000 美元。抗癌药物价格是该国最高的;这些药物比欧洲的药物贵两倍多,比世界其他地区的药物贵两到六倍。以下是一些国家肺癌治疗的费用:
国家
|
治疗费用范围
|
印度 | 100,000–2,00,000 印度卢比(1,203.01–2,406.02 美元) 100,000–2,00,000 (US$ 1,203.01–2,406.02) |
我们 | 25,000 美元至 50,000 美元 |
尼日利亚 | 5,540,000–9,000,000 奈拉(721.56–1,172.2 美元) |
肯尼亚 | 100,000–300,000 肯尼亚先令 (668.22–2,004.66 美元).100,000–300,000 (US$ 668.22–2,004.66) |
加纳 | 80,000–2,00,000 加纳塞地(6,823.44–17,058.6 美元) 80,000–2,00,000 (US$ 6,823.44–17,058.6) |
火鸡 | 180,000–22,000 里拉(6,512–7,959.12 美元) 180,000–22,000 (US$ 6,512–7,959.12) |
德国 | 18,000–25,000 欧元(19,046.5–26,453.5 美元) |
许多抗癌药物的月费用大大超过大多数家庭的收入。因此,研究人员面临着巨大的压力,需要限制成本并证明其价值。许多国家的政治不确定性和持续的经济压力引发了人们对公共医疗资金可持续性的担忧。在较不富裕的国家,缺乏具有成本效益的药物影响了人口的健康状况,导致平均预期寿命较低。在没有全民医疗保健和医疗保险提供者的国家,患者必须自掏腰包支付治疗费用。与药物相关的高成本限制了肿瘤药物制造商的收入,因为这些药物只能提供给富裕人群和拥有有效保险覆盖的人。因此,药物和手术的高成本阻碍了肺癌治疗市场的增长。
定制研究以满足您的需求
我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。
肺癌治疗市场:
Lung Cancer Therapy Market: Strategic Insights
Lung Cancer Therapy Market
-
CAGR (2022 - 2030)
12.7%
-
Market Size 2022
US$ 31.02 Billion
-
Market Size 2030
US$ 80.49 Billion
Market Dynamics
GROWTH DRIVERS
- 肺癌病例不断增加
- 政府推出肺癌筛查和治疗举措
FUTURE TRENDS
- 靶向治疗需求不断增长
OPPORTUNITIES
- 临床试验中肺癌治疗的数量不断增加
Key Players
- Medtronic PLC
- RF Medical Co Ltd
- Johnson Johnson
- Merck KGaA
- Sun Pharmaceutical Industries Ltd
- Bioventus Inc
- Meiji Seika Pharma Co Ltd
- Advanz Pharma Corp
- Olympus Corp
Regional Overview
- 北美(美国、加拿大、墨西哥)
- 欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
- 亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
- 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
- 中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)
Market Segmentation
治疗类型(非侵入性和微创性)
适应症(非小细胞肺癌及小细胞肺癌)
最终用户(医院、肿瘤诊所、研究中心等)
地理(北美洲、欧洲、亚太地区、中东和非洲、南美洲和中美洲)
Lung Cancer Therapy Market: Strategic Insights
-
CAGR (2022 - 2030)12.7% -
Market Size 2022
US$ 31.02 Billion -
Market Size 2030
US$ 80.49 Billion
Market Dynamics
- 肺癌病例不断增加
- 政府推出肺癌筛查和治疗举措
- 靶向治疗需求不断增长
- 临床试验中肺癌治疗的数量不断增加
Key Players
- Medtronic PLC
- RF Medical Co Ltd
- Johnson Johnson
- Merck KGaA
- Sun Pharmaceutical Industries Ltd
- Bioventus Inc
- Meiji Seika Pharma Co Ltd
- Advanz Pharma Corp
- Olympus Corp
Regional Overview
- 北美(美国、加拿大、墨西哥)
- 欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
- 亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
- 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
- 中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)
Market Segmentation
复合年增长率(2022 - 2030 年)12.7%- 2022 年市场规模
310.2 亿美元 - 2030 年市场规模
804.9 亿美元
市场动态
- 肺癌病例增加
- 政府针对肺癌筛查和治疗的举措
- 靶向治疗需求不断增长
- 临床试验中肺癌治疗的数量不断增加
关键人物;主力;重要一员
- 美敦力公司
- RF医疗有限公司
- 强生公司
- 默克公司
- 太阳制药工业有限公司
- Bioventus公司
- 明治制药株式会社
- Advanz 制药公司
- 奥林巴斯公司
区域概况
- 北美
- 欧洲
- 亚太
- 南美洲和中美洲
- 中东和非洲
市场细分
- 无创和微创
- 非小细胞肺癌和小细胞肺癌
- 医院
- 肿瘤诊所
- 研究中心
- 其他的
- 北美
- 欧洲
- 亚太地区
- 中东和非洲
- 南美洲和中美洲
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
报告细分和范围:
肺癌治疗市场根据治疗类型、适应症、最终用户和地理位置进行划分。按疫苗类型,肺癌治疗市场分为无创和微创。微创部分进一步分为射频消融、微波消融、热消融、冷冻消融、化学消融、光动力消融等。按适应症,肺癌治疗市场分为非小细胞肺癌和小细胞肺癌。按最终用户,市场分为医院、肿瘤诊所、研究中心等。根据地域划分,肺癌治疗市场分为北美(美国、加拿大和墨西哥)、欧洲(英国、德国、法国、意大利、西班牙、俄罗斯和欧洲其他地区)、亚太地区(中国、日本、印度、韩国、澳大利亚、东南亚和亚太其他地区)、中东和非洲(阿联酋、沙特阿拉伯、南非和中东和非洲其他地区)以及南美洲和中美洲(巴西、阿根廷和南美洲和中美洲其他地区)。
节段分析:
根据疫苗类型,肺癌治疗市场分为非侵入性和微创性。微创部分进一步分为射频消融、微波消融、热消融、冷冻消融、化学消融、光动力消融等。2022 年,非侵入性治疗部分占据了更大的市场份额。微创部分预计将在 2022-2030 年期间录得更高的复合年增长率。放射治疗、化学治疗和靶向治疗是主要的非侵入性肺癌治疗方法。放射肺癌治疗使用高能和强大的 X 射线来消除癌细胞,控制其生长并阻止其在肺部内扩散。放射治疗用于手术前后,以在手术前缩小肿瘤并杀死手术后持续存在的癌细胞。在化疗中,药物用于杀死肺部新的或现有的癌细胞。化疗被认为是肺癌的重要治疗方法。根据 2023 年发表的《化疗统计》一文,大约 2% 的 1 期和 2 期患者、9% 的 3 期患者和 27% 的 4 期患者接受化疗来治疗肺癌。
微创部分进一步细分为射频消融、微波消融、热消融、冷冻消融、化学消融、光动力消融等。光动力消融是一种未被充分利用的疗法,通过产生活性氧来选择性地破坏癌细胞。这种疗法已在临床和体外环境中得到广泛研究。已经进行了各种研究来检查光动力消融疗法与纳米粒子联合用于肺癌患者的疗效。
射频消融 (RFA) 是针对癌症患者(包括无法手术的 NSCLC 患者)的最新且最有前景的治疗方法。RFA 具有很高的可行性和安全性,可以利用热的生物效应对肿瘤造成不可逆损伤或凝固性坏死。近年来,越来越多的医院开始选择 RFA 而不是立体定向放射治疗 (SBRT) 作为早期诊断的 NSCLC 的非手术治疗选择。因此,光动力消融治疗研究活动的增加和对射频消融治疗的日益偏好正在推动肺癌治疗市场在 RFA 领域的增长。微波消融技术使用细针将微波传输到肝肿瘤中,以热量破坏癌细胞。
化学消融术是将化学混合物注入静脉,然后使用超声成像进行观察的技术。从无水乙醇和冰醋酸到表霉素等不同药物的应用和组合已在临床上进行了长期测试。
区域分析:
根据地域,肺癌治疗市场分为北美、欧洲、亚太地区、中东和非洲以及南美和中美洲。北美是全球肺癌治疗市场增长的最大贡献者。预计亚太地区在 2022-2030 年期间的肺癌治疗市场复合年增长率最高。美国肺癌治疗市场的增长主要受到肺癌病例发病率增加、产品推出和政府举措的推动。肺癌是美国第二大常见癌症。根据美国癌症协会的数据,截至 2023 年,美国约有 238,340 名成年人(117,550 名男性和 120,790 名女性)被诊断出患有肺癌;此外,约有 127,070 人(67,160 名男性和 59,910 名女性)死于该疾病。肺癌占所有癌症死亡人数的五分之一,是美国癌症死亡的主要原因。根据同一来源,NSCLC 占所有肺癌诊断的 81%。因此,美国肺癌发病率的上升推动了美国肺癌治疗市场的增长。
公司推出的各种治疗肺癌的产品也促进了市场的增长。2021 年 5 月,美国 FDA 批准 Lumakras (sotorasib) 作为首个针对成人非小细胞肺癌患者的靶向疗法。这是首个获批用于 KRAS 突变肿瘤的靶向疗法,该突变占非小细胞肺癌 (NSCLC) 病例报告突变的约 25%。2021 年 5 月,美国 FDA 加速批准 Rybrevant (amivantamab-vmjw),这是一种针对表皮生长因子 (EGF) 和 MET 受体的双特异性抗体,用于治疗包含 EGFR 外显子 20 插入突变的局部晚期或转移性 NSCLC 成人患者。
肺癌治疗市场报告范围
报告属性 | 细节 |
---|---|
2022 年市场规模 | 310.2亿美元 |
2030 年的市场规模 | 804.9亿美元 |
全球复合年增长率(2022 - 2030 年) | 12.7% |
历史数据 | 2020-2021 |
预测期 | 2023-2030 |
涵盖的领域 | 按治疗类型
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
行业发展和未来机遇:
以下列出了肺癌治疗市场主要参与者的各种举措:
- 2023年10月,强生公司提交了II类扩展适应症申请,寻求欧洲药品管理局(EMA)批准RYBREVANT(amivantamab)联合化疗(卡铂和培美曲塞)用于一线治疗患有活化表皮生长因子受体(EGFR)外显子20插入突变的晚期非小细胞肺癌(NSCLC)成年患者。
- 2022年12月,RF医疗有限公司宣布,FDA批准其专利的MYGEN M-3004发生器和MYOBLATE射频消融系统在美国进行商业化。这些设备用于治疗受损的肿瘤和组织。
- 2021年5月,强生旗下杨森制药公司宣布,美国FDA加速批准RYBREVANTTM(amivantamab-vmjw)用于治疗EGFR外显子20插入突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者。该药物适用于铂类化疗期间或之后病情进展的患者。RYBREVANTTM是首个获批用于治疗NSCLC患者的全人源双特异性抗体,靶向EGFR外显子20插入突变,这是第三大最常见的EGFR激活突变。
竞争格局和重点公司:
肺癌治疗市场中的一些知名企业包括美敦力公司、RF Medical Co Ltd、强生公司、默克公司、太阳制药工业有限公司、Bioventus Inc、明治制果制药有限公司、Advanz Pharma Corp 和奥林巴斯公司。这些公司专注于新产品的推出和地域扩张,以满足全球日益增长的消费者需求,并增加其专业产品组合中的产品范围。它们的全球影响力使它们能够服务于庞大的客户群,从而促进市场扩张。
Lung Cancer Therapy Market Report Scope
Report Attribute | Details |
---|---|
Market size in | US$ 31.02 Billion |
Market Size by | US$ 80.49 Billion |
Global CAGR | 12.7% |
Historical Data | 2020-2021 |
Forecast period | 2023-2030 |
Segments Covered |
By 治疗类型(非侵入性和微创性) |
Regions and Countries Covered |
北美(美国、加拿大、墨西哥)
|
Market leaders and key company profiles |
|
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The lung cancer therapy market is analyzed on the basis of disease indication, type, offering, technology, and end user. Based on therapy type, the lung cancer therapy market is segmented into non-invasive and minimally invasive. Minimally Invasive segment is further classified into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others. In 2022, the noninvasive therapy segment held a larger market share. The minimally invasive segment is expected to record a higher CAGR during 2022–2030.
The lung cancer therapy market majorly consists of the players such Medtronic PLC, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Meiji Seika Pharma Co Ltd, Advanz Pharma Corp, and Olympus Corp among others.
The increasing cases of lung cancer, and government initiatives for the screening and treatment of lung cancer bolster the lung cancer therapy market size. However, the high cost of lung cancer therapy hinders the lung cancer therapy market growth.
The most common treatment for lung cancer includes surgery, radiotherapy, chemotherapy, and immunotherapy. Lung cancer now a days is treated by targeted therapy, a type of personalized medicine, is a combination of two or more drugs, designed to directly target the cancerous cells. Therapies such as ablation and chemotherapy destroy healthy cells along with infected cells, which can affect the overall patient condition. Targeted therapy is designed in a way to selectively kill cancerous cells, keeping the function of healthy cells unhampered. With recent developments in medical technologies, focus on the use of targeted therapy for the treatment of lung cancer is increasing notably. Scientists are focusing on studying lung cancer cell mutations that are responsible for driving the uncontrolled growth of cancerous cells.
The List of Companies - Lung Cancer Therapy Market
- Medtronic PLC
- RF Medical Co Ltd
- Johnson & Johnson
- Merck KGaA
- Sun Pharmaceutical Industries Ltd
- Bioventus Inc
- Meiji Seika Pharma Co Ltd
- Advanz Pharma Corp
- Olympus Corp
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.